Topical Cysteamine to Tx Corneal Cystine Crystal Accumulation in Cystinosis

这项研究最初是为了测试局部应用半胱胺治疗半胱氨酸病患者角膜半胱氨酸晶体积聚的疗效。它始于1986年，到1993年，半胱胺滴剂的功效已经确立，当时苯扎溴铵被添加到配方中作为防腐剂。在接下来的几年里，研究了该公式的两个变体，都没有证明像原始公式那样有效。该配方由0.5%的半胱胺和苯扎溴铵组成，自2001年以来一直在使用。它于2012年获得FDA批准，并于2013年5月通过Sigma-Tau制药公司上市。

This study was originally designed to test the efficacy of topical cysteamine for the treatment of corneal cystine crystal accumulation in patients with cystinosis. It was started in 1986, and by 1993 the efficacy of cysteamine drops had been established, at which time benzalkonium was added to the formulation as a preservative. In the years that followed, two variations of the formula were studied, neither proving as efficacious as the original. That formula, consisting of cysteamine 0.5% plus benzalkonium, has been used since 2001. It received FDA approval in 2012, and was available commercially through Sigma-Tau Pharmaceuticals as of May 2013.